Research progress in prevention and cure of glucagon-like peptide-1 receptor agonists-1 receptor agonists for diabetic retinopathy
10.3760/cma.j.cn511434-20230424-00184
- VernacularTitle:胰高血糖素样肽-1受体激动剂类药物防治2型糖尿病视网膜病变的研究进展
- Author:
Cenyi WU
1
;
Xiaoxia LI
;
Yu SHEN
;
Miaoqin WU
Author Information
1. 浙江中医药大学第二临床医学院，杭州 310053
- Keywords:
Diabetic retinopathy;
Glucagon-like peptide-1 receptor agonist;
Semaglutide;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2024;40(2):153-158
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy (DR) is one of the most frequent complications of diabetes (T2DM), which is the main eye disease causing blindness in adults in recent years. At present, glucagon-like peptide-1 receptor agonists (GLP-1RA) have become the main drugs used in the treatment of diabetes due to its superior hypoglycemic, lipid-lowering, hypertensive and cardiovascular effects. A large number of studies have shown that GLP-1RA drugs can protect retinal microvascular and optic nerves in the treatment of diabetes through various ways, but some studies have found that GLP-1RA drugs represented by semaglutide may lead to the progress of DR. Therefore, GLP-1RA should be used cautiously for patients who with severe non-proliferative DR or proliferative DR. Regardless of whether T2DM patients are complicated with DR, the fundus retinal condition should be monitored regularly after the use of GLP-1RA drugs, and timely countermeasures should be taken when DR occurs and develops. The benefits of GLP-1RA used by diabetes patients are obvious to all, and scientific and rational drug use can prevent the occurrence and progress of DR, which can better benefit DR Patients.
